Home Featured Page 290

Featured

Latest

The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science

Megan Bowers & Mikayla Hellwich: MDMA History, Harm Reduction, and the Problem With Prohibition

Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly; Turnbull Doubles Down on BOL-148; Compass Talks Indication Expansion, Could VA Help?

From Sonora to Big Pharma: Kimon de Greef Traces the Strange Rise of 5-MeO-DMT

Psychedelic Alpha Crossword: Summer 2026

Nova Mentis Announces Promising Research Results

MindMed Announces the Addition of Stanford University Neuroscientist as Chair of...

Horizons ETFs Completes Rebalance of World’s First Psychedelics ETF

Champignon Brands Announces Filing of Listing Statement

Psychedelic Bulletin: UW-Madison Launches Psychedelic Master’s Program; COMPASS Granted 2 Patents

Early Clinical Research History of DMT

Havn Life Sciences Signs LOI to Research and Develop Medical Psilocybin...

Psychedelic vs. Hallucinogen-What’s in a Name?

EDITOR PICKS

The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science

Megan Bowers & Mikayla Hellwich: MDMA History, Harm Reduction, and the...

Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science

Megan Bowers & Mikayla Hellwich: MDMA History, Harm Reduction, and the Problem With Prohibition

Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly; Turnbull Doubles Down on BOL-148; Compass Talks Indication Expansion, Could VA Help?

From Sonora to Big Pharma: Kimon de Greef Traces the Strange Rise of 5-MeO-DMT

Psychedelic Alpha Crossword: Summer 2026

Senior Program Director

Nova Mentis Announces Promising Research Results

MindMed Announces the Addition of Stanford University Neuroscientist as Chair of...

Horizons ETFs Completes Rebalance of World’s First Psychedelics ETF

Champignon Brands Announces Filing of Listing Statement

Psychedelic Bulletin: UW-Madison Launches Psychedelic Master’s Program; COMPASS Granted 2 Patents

Early Clinical Research History of DMT

PTSF52 – Start Low, Go Slow

Havn Life Sciences Signs LOI to Research and Develop Medical Psilocybin...

Psychedelic vs. Hallucinogen-What’s in a Name?

EDITOR PICKS

The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science

Megan Bowers & Mikayla Hellwich: MDMA History, Harm Reduction, and the...

Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY